Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Stephen Allen Hurly M.B.A., M.Sc. | CEO, President & Executive Director | -- | -- | 1968 |
| Mr. Fred M. Powell CPA | Chief Financial Officer | -- | -- | 1961 |
| Ms. Oxana Polyakova Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Amy Garabedian J.D. | General Counsel & Corporate Secretary | -- | -- | 1976 |
| Mr. Wouter van Hunnik | VP & Head of Human Resources | -- | -- | -- |
| Dr. Hans van der Vliet M.D., Ph.D. | Head of Innovation | -- | -- | 1975 |
| Dr. Ton Adang Ph.D. | Chief Development Officer | -- | -- | 1961 |
| Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D. | Chief Medical Officer | -- | -- | 1965 |
LAVA Therapeutics N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 37
Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Corporate Governance
Upcoming Events
March 18, 2025 at 12:30 PM UTC - March 24, 2025 at 12:30 PM UTC
LAVA Therapeutics N.V. Earnings Date
Recent Events
Recent Events Information Not Available